نتایج جستجو برای: dipeptidyl peptidase iv

تعداد نتایج: 187377  

2015
Lucie Sromova Petr Busek Liliana Sedova Aleksi Šedo

Title:Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity

Journal: :Gastroenterology 2011
Linhua Xu Giatgen A Spinas Markus Niessen

2016
Jennifer Hayes Rosie Anderson Jeffrey W Stephens

Type 2 diabetes mellitus is a progressive disease associated with significant morbidity and mortality. There is good evidence showing that intensive glycemic control reduces the development and progression of complications. In order to achieve glycemic targets, patients often require a combination of oral therapy and/or insulin in addition to lifestyle modification. Unfortunately, many of the t...

2017
John B. Buse M. Angelyn Bethel Jennifer B. Green Susanna R. Stevens Yuliya Lokhnygina Pablo Aschner Carlos Raffo Grado Tsvetalina Tankova Julio Wainstein Robert Josse John M. Lachin Samuel S. Engel Keyur Patel Eric D. Peterson Rury R. Holman

OBJECTIVE We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i). RESEARCH DESIGN AND METHODS In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, a cardiovascular safety study of sitagliptin, all suspected cases ...

Journal: :Hospital pharmacy 2014
Patricia A Howard

Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some hav...

2017
Saori Tsuchiya Evan Friedman Carol Addy Akira Wakana Daniel Tatosian Yuki Matsumoto Hideyo Suzuki Eunkyung Kauh

AIMS/INTRODUCTION Omarigliptin is a novel, potent, long-acting oral dipeptidyl peptidase-4 inhibitor being developed as a once-weekly (q.w.) treatment for type 2 diabetes mellitus patients, with 25 mg and 12.5 mg tablets recently being approved as market formulations in Japan. MATERIALS AND METHODS This was a two-part, double-blind, randomized, placebo-controlled study in healthy Japanese men...

2017
Hitoshi Ishii Yuki Suzaki Yuko Miyata

INTRODUCTION Long-term glycemic control in type 2 diabetes is critical to prevent or delay the onset of macrovascular and microvascular complications. Medication adherence is an integral component of type 2 diabetes management. Minimizing the dosing frequency of antidiabetic drugs may reduce treatment burden for patients and improve medication adherence. This study has been proposed to assess t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید